US Stock Market Move | Novartis AG Sponsored ADR Pharmaceutical (NVS.US) rose over 5% after successful late-stage trials of the MS oral medication.

On Tuesday, Novartis AG Sponsored ADR (NVS.US) rose by over 5%, reaching $160.82. In terms of news, Novartis AG Sponsored ADR announced that trials showed patients treated with remibrutinib had reduced relapse rates and fewer brain lesions compared to those treated with teriflunomide, with no liver safety signals observed. This drug is expected to provide Novartis AG Sponsored ADR with a novel oral treatment for multiple sclerosis, serving as a follow-up to its blockbuster Kesimpta series. This achievement further strengthens the market prospects for BTK inhibitors, which aim to suppress harmful immune responses in diseases. Previously, similar drugs from Sanofi and Merck failed to outperform teriflunomide in late-stage trials regarding relapse rates. The drug may also intensify competition with Roche. Novartis AG Sponsored ADR plans to submit a global application for remibrutinib for the treatment of multiple sclerosis, with detailed results to be announced later this year at a medical conference in Toronto. The drug is currently approved in the U.S. and Europe for the treatment of chronic spontaneous urticaria, a skin condition characterized by recurrent hives.